Lilly halted the development of Alzheimer's disease treatment semagacestat as two late-stage studies showed the drug didn't slow the disease's progression and may have worsened patients' conditions.
WSJ.com: What's News US, Wall Street Journal
Tue, 08/17/2010 - 9:54am
Lilly halted the development of Alzheimer's disease treatment semagacestat as two late-stage studies showed the drug didn't slow the disease's progression and may have worsened patients' conditions.